Comparison of a Phytotherapeutic Agent (Permixon) with an α-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

Debruyne, F.M.J.; Koch, Gary G.; Boyle, Peter; Silva, Fernando Calais da; Gillenwater, J.G.; Hamdy, Freddie C.; Perrin, Paul B.; Teillac, P.; Vela-Navarrete, R.; Raynaud, Jean

doi:10.1016/s0302-2838(02)00066-0

Cited by 158 publications

(134 citation statements)

References 29 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…The effect of D-004 on this variable, however, should not be interpreted as a proof of efficacy, as recent reports show controversial results of the use of this marker. The lack of effect of SP on this variable agrees with other reports [46].The treatments were well tolerated, consistent with previous data [25][26][27][28]40]. Safety indicators and sexual performance were not impaired by the treatments, which agree with previous reports on SP [11,12,46], and being the first report on this matter for D-004.…”

Section: Discussionsupporting

confidence: 91%

Comparative Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts On Blood Oxidative Variables in Men with Benign Prostate Hyperplasia (BPH)

Guzman¹

2013

iosrphr

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Comparative Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts On Blood Oxidative Variables in Men with Benign Prostate Hyperplasia (BPH)

Guzman¹

2013

iosrphr

View full text Add to dashboard Cite

show abstract

“…The best described and studied phytotherapeutic agent, Serenoa repens (saw palmetto), has shown mild to moderate efficacy in reducing nocturia, increasing maximal urinary flow and improving International Prostate Symptom Score (IPSS) in men with BPH, 40,41 with results comparable with that of tamsolusin. 40,42,43 However, other trials have shown no significant beneficial effect of S. repens compared with placebo, 44 and a recent Cochrane Review concluded that S. repens was not more effective than placebo for the treatment of urinary symptoms consistent with BPH. 45 Pygeum africanum, an extract from the African prune tree, is another popular alternative remedy for BPH, 46 and has been shown in a Cochrane review to provide moderate relief from the urinary problems caused by BPH.…”

Section: Phytochemicalsmentioning

confidence: 99%

Diagnosis and management of benign prostatic hyperplasia in primary care

Tanguay

Awde

Brock

et al. 2013

CUAJ

View full text Add to dashboard Cite

S92colleagues 7 showed that the percentage of men who pursue active treatment, as opposed to watchful waiting, was notably greater for those seen by a urologist regardless of LUTS severity. 4 Urologists and primary care physicians also differed in their choice of therapy. Urologists prescribed 5-alpha-reductase inhibitors (5-ARIs), combination therapy with an alpha-blocker and 5-ARI, and an anticholinergic therapy significantly more often than primary care physicians. 4 Primary care physicians, on the other hand, prescribed nonselective alpha-blockers more often than urologists. 4 It is not apparent why these differences exist, but it is possible that primary care physicians view LUTS mostly as a quality of life (QOL) issue and are less concerned with the progressive nature of the disease. 4 It could also be due to the fact that patients with similar symptoms but who are more bothered about them are referred along to a urology specialist for management. That being said, many feel that a "shared care" approach to the diagnosis and treatment of BPH should be adopted. 3,8 Primary care physicians are better positioned to identify men with LUTS and those at risk for disease progression, and should consider treatment for those men with mild to moderate symptoms without evidence of prostate cancer. In contrast, men with more severe symptoms requiring urgent or emergent treatment (such as surgery) should be seen by a urologist.3 Thus, educating primary care physicians regarding changes in the management of BPH and progression is very important. This article aims to assist physicians in the diagnosis and treatment of BPH in the primary care setting so as to: (1) facilitate access to needed care; (2) improve long-term outcomes of LUTS management and stop the progression of BPH; and (3) avoid surgical consultations in cases where primary care management is sufficient. Diagnosis and management of benign prostatic hyperplasia in primary care REVIEW AbstractBenign prostatic hyperplasia (BPH), and its clinical manifestation as lower urinary tract symptoms (LUTS), is a major health concern for aging men. There have been significant advances in the diagnosis and treatment of BPH in recent years. There has been a renewed interest in medical therapies and less invasive surgical techniques. As a consequence, the treatment needs of men with mild to moderate LUTS without evidence of prostate cancer can now be accomplished in a primary care setting. There are differences in the way urologists and primary care physicians approach the evaluation and management of LUTS due to BPH, which is not reflected in Canadian Urological Association (CUA) and American Urological Association (AUA) guidelines. A "shared care" approach involving urologists and primary care physicians represents a reasonable and viable model for the care of men suffering from LUTS. The essence of the model centres around educating and communicating effectively with the patient on BPH. This article provides primary care physicians with an overview of the diagnostic and m...

show abstract

“…Os autores consideram inúmeras limitações metodológicas, incluindo a curta duração (13 semanas), o insucesso no uso de escores de sintomas validados e indicação do tratamento ocultada em 10 dos 21 estudos avaliados. Ainda, segundo Debruyne et al (2002), durante a Conferência Internacional de Doenças Urológicas para discutir a HBP e seu tratamento, relatou-se uma falta de estudos clínicos controlados, randomizados, multicêntricos e de longa duração para o saw palmetto. Considera-se de grande importância o estudo de novos compostos efi cazes, de baixo custo e com mínimo de efeitos adversos para o tratamento da HBP.…”

Section: Resultsunclassified

Estudo exploratório da utilização de saw palmetto no tratamento da hiperplasia benigna da próstata por urologistas de Porto Alegre

Ferreira¹,

Castro²,

Bridi³

2008

Rev. bras. farmacogn.

View full text Add to dashboard Cite

RESUMO:O objetivo deste trabalho foi avaliar a utilização de fi toterápicos a base de saw palmetto na terapia sintomática da hiperplasia benigna da próstata (HBP) por médicos urologistas da cidade de Porto Alegre. Consistiu em um estudo transversal, exploratório, por meio de entrevista semi-estruturada aplicada a urologistas de Porto Alegre. A amostra foi obtida utilizando catálogo do plano de saúde UNIMED-Porto Alegre. A randomização foi realizada através de sistemática aleatória, sendo sorteados trinta e cinco médicos, dos quais 21 foram selecionados para realização da pesquisa através de questionário. Todos os urologistas entrevistados avaliam e tratam pacientes com hiperplasia benigna da próstata. O saw palmetto não foi citado como terapia medicamentosa de 1ª ou 2ª escolhas no tratamento da HBP. O grupo farmacológico mais freqüentemente utilizado para o tratamento da HBP foi ∝-bloqueadores. Mais da metade dos médicos entrevistados relata ter conhecimento sobre a utilização do saw palmetto, principalmente através de artigos científi cos. Os resultados indicam que o saw palmetto não é prescrito pelos urologistas em Porto Alegre, todavia a maior parte destes profi ssionais tem conhecimento sobre sua utilização.Unitermos: Serenoa repens, Arecaceae, saw palmetto, HBP, estudo exploratório, urologistas, Porto Alegre.ABSTRACT: "Investigation study concerning the saw palmetto use for the benign prostatic hyperplasia treatment by urologists in Porto Alegre". The aim of this work was to assess the prescription of saw palmetto phytomedicines for improving symptoms of benign prostatic hyperplasia (BPH) by urologists in Porto Alegre (Brazil). The study was transversal and exploratory consisting of a semi-structured interview with urologists. The sample was obtained from the UNIMED Catalog -Porto Alegre (Brazil). The randomization was made by chance, being selected thirty-fi ve physicians. The fi rst twenty-one who accepted to participate were interviewed. All the interviewed urologists treat patients with benign prostatic hyperplasia. The saw palmetto was not mentioned as the fi rst or second choice for treating BPH. The α-blockers were the most mentioned pharmacological group. However, more than half of urologists have heard about the use of saw palmetto and most of them gathered the information in scientifi c papers. The results indicate that saw palmetto is not prescribed for urologists in Porto Alegre, although most of them have knowledge about this phytomedicine.

show abstract

Comparison of a Phytotherapeutic Agent (Permixon) with an α-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

Cited by 158 publications

References 29 publications

Comparative Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts On Blood Oxidative Variables in Men with Benign Prostate Hyperplasia (BPH)

Comparative Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts On Blood Oxidative Variables in Men with Benign Prostate Hyperplasia (BPH)

Diagnosis and management of benign prostatic hyperplasia in primary care

Estudo exploratório da utilização de saw palmetto no tratamento da hiperplasia benigna da próstata por urologistas de Porto Alegre

Contact Info

Product

Resources

About